Forte Biosciences Inc(FBRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.13 | Insider Own | 18.48% | Shs Outstand | 20.5M | Perf Week | - |
| Market Cap | 1.63B | Forward P/E | - | EPS next Y | -31.68% | Insider Trans | - | Shs Float | 17.3M | Perf Month | 0.5% |
| Enterprise Value | 1.44B | PEG | - | EPS next Q | - | Inst Own | 74.56% | Short Float | 9.43% | Perf Quarter | 361.29% |
| Income | -0.09B | P/S | - | EPS this Y | 31.63% | Inst Trans | 32.4% | Short Ratio | 1.23 | Perf Half Y | 154.26% |
| Sales | 0.00B | P/B | 8.58 | EPS next 5Y | - | ROA | -56.1% | Short Interest | 1.63M | Perf YTD | 182.32% |
| Book/sh | 8.97 | P/C | 8.24 | EPS past 3/5Y | 38.19% 50.46% | ROE | -62.28% | 52W High | -0.27% ($77.20) | Perf Year | 583.75% |
| Cash/sh | 9.35 | P/FCF | - | Sales past 3/5Y | - | ROIC | -47.85% | 52W Low | 661.52% ($10.11) | Perf 3Y | 266.62% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 35.82% | Gross Margin | - | Volatility(W/M) | 0.08% 0.17% | Perf 5Y | -88.73% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.01 | EPS Q/Q | -2.4% | Profit Margin | - | RSI (14) | 84.42 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.01 | Sales Q/Q | - | SMA20 | 0.21% ($76.83) | Beta | 2.23 | Target Price | $77 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/08/17 | SMA50 | 45.99% ($52.74) | Rel Volume | 0 | Prev Close | $76.99 |
| Employees | 19 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -6.9% - | SMA200 | 138.99% ($32.21) | Avg Volume(3M) | 1.33M | Price | $76.99 |
| IPO | 2017/4/13 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
🧬 Forte Biosciences trades on the US stock market under the ticker FBRX and is a US clinical-stage biotech company targeting autoimmune diseases. Its lead candidate, FB102, is an anti-CD122 monoclonal antibody being developed for multiple autoimmune indications, including celiac disease, vitiligo, and alopecia areata. As a research-and-development-driven company with no revenue, its corporate value is largely dictated by clinical data outcomes.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
FBRX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +31.6% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -88.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 74.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #125 of 595 in the industry
Based on market cap of $2B.
RARE#122 Ultragenyx Pharmaceutical Inc $2B PER - 
REPL#123 Replimune Group Inc $2B PER - 
URGN#124 UroGen Pharma Ltd $2B PER - FBRX#125 Forte Biosciences Inc $2B PER - 
IMCR#125 Immunocore Holdings plc ADR $2B PER - 
FAQ
What kind of company is FBRX?
FBRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of FBRX?
The market cap of FBRX is approximately $1.6B, ranking 2,299 within its sector.
What is the 52-week high and low for FBRX?
FBRX has recorded a 52-week high of $77.20 and a low of $10.11.
